H.C. Wainwright analyst Andrew Fein maintained a Hold rating on Syros Pharmaceuticals (SYRS) today and set a price target of $10. The company’s shares closed yesterday at $7.51, close to its 52-week low of $6.25.
“Our price target of $10/share ($2.92 from tamibarotene + $3.50 from platform + $3.46 in cash) is based on a discounted cash flow analysis (2018-2027) using a 12% discount rate and 1% growth rate, in line with the expected discount and growth parameters of a development-stage oncology company. Risks to our investment thesis and target price include: (1) failure in clinical studies; (2) failure to secure regulatory approval; and (3) smaller than anticipated commercial opportunity due to market size, competition, and pricing.”
According to TipRanks.com, Fein is a 5-star analyst with an average return of 9.1% and a 45.3% success rate. Fein covers the Healthcare sector, focusing on stocks such as Proteostasis Therapeutics Inc, ACADIA Pharmaceuticals Inc, and Strongbridge Biopharma Plc.
Syros Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $20.75.
The company has a one-year high of $14.90 and a one-year low of $6.25. Currently, Syros Pharmaceuticals has an average volume of 122K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Syros Pharmaceuticals, Inc. engages in the development of novel gene control therapies for cancer and other diseases. It has developed a proprietary platform that is designed to systematically and efficiently analyze unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations.